INDUSTRY NEWS: The Next Chapter of Progress in HER2-Positive Early Breast Cancer

A significant step toward improving access to treatment for Canadians with HER2-positive early breast cancer was reached this month, following the completion of negotiations between Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) for Perjeta (pertuzumab) in the neoadjuvant setting. The agreement brings Canadian patients one step closer to publicly funded access to Perjeta in […]